Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > Affymax Jumps Most in 16 Months on FDA Anemia-Drug Review

FDAnews Drug Daily Bulletin

Dec. 7, 2011 | Vol. 8 No. 238

Affymax Jumps Most in 16 Months on FDA Anemia-Drug Review

Affymax surged the most in the 16 months after U.S. regulators said the company’s experimental anemia medicine works as well as drugs sold by Amgen and Johnson & Johnson for chronic kidney disease.
Bloomberg

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Pharma Blog Watch New Report Examines Efforts to Reduce the Impact of Generic Competition for Lipitor Royal Endorsement for UAE’s Newest Drugmaker Pathway Genomics to Offer BRCA Test

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.